Brussels, Belgium, July 16, 2014

Merodis, an independent corporate finance advisory boutique, is proud to add another transaction to its Life Sciences OTC/OTX transaction list. This follows the successful execution of the sale of dermatology company Despharma to Omega Pharma, one of the European leading specialists in OTC medecines and healthcare products.

Despharma is a company focusing on the research and development of innovative, safe and efficacious topical dermatology products. Despharma has developed, tested, and registered a range of products for the treatment of autoimmune related skin disorders, such as atopic dermatitis, contact dermatitis and psoriasis. Since 2009, it had out licensed several of its ‘skin barrier repair’ products to Omega Pharma and whom marketed the Despharma products and technology under Omega Pharma’s own brand Dermalex®. Despharma has operations near Budapest, Hungary and in the Netherlands.

With this acquisition Omega Pharma gains full ownership of all Despharma technology, know-how and IP related to several clinically proven and steroid free treatments for amongst others eczema and psoriasis products and which will enable Omega Pharma to accelerate and extend the ongoing roll-out of its Dermalex® product offering on an international level.

For more information, please contact:

Dirk Marckx
dma@merodis.com , +32 495 38 17 81
Gerd Philippaerts
gph@merodis.com , +32 488 25 65 23